Discovering the Delicate Balance of T Cell Responses
T cells, a critical component of the adaptive immune system, play a pivotal role in defending the body against pathogens by recognizing specific antigens presented on major histocompatibility complex (MHC) molecules. Helper T cells, or CD4-positive T cells, coordinate immune responses by activating other immune cells like B cells and cytotoxic T cells. However, unchecked T cell activity can lead to hyperimmune responses, contributing to autoimmune diseases where the immune system attacks healthy tissues. In Japan, where rheumatoid arthritis affects approximately 1% of the population and systemic lupus erythematosus impacts over 74,000 individuals, precise regulation of these responses is crucial for developing targeted therapies.
Researchers at Osaka University have long been at the forefront of immunology, with institutions like the Immunology Frontier Research Center (IFReC) and the Research Institute for Microbial Diseases (BIKEN) driving groundbreaking discoveries. These centers have positioned Osaka University as a global leader in immunology, frequently topping rankings for citation impact in the field.
Osaka University's Breakthrough: Immune-Induced TCR-Like Antibodies
In a study published in Nature Communications on April 16, 2026, a team led by Kazuki Kishida and Professor Hisashi Arase from BIKEN uncovered a novel mechanism: the production of 'immune-induced TCR-like antibodies' or iTabs during standard immune responses to protein antigens such as hen egg lysozyme (HEL). These antibodies specifically recognize the antigen peptide bound to MHC class II (pMHCII) complexes, mimicking the specificity of T cell receptors (TCRs).
The discovery stemmed from immunizing mice with full protein antigens or peptides containing flanking residues (FR)—extra amino acids naturally attached during antigen processing. Unlike minimal peptides lacking FR, FR-containing peptides triggered iTab production. These iTabs bound exclusively to the specific pMHCII, blocking TCR engagement and suppressing antigen-specific CD4 T cell activation.
This antigen-specific suppression represents a built-in feedback loop, preventing excessive immunity after pathogen clearance.
Unraveling the Methods: From Immunization to Cryo-EM Insights
The Arase lab employed a multi-step approach. Mice were immunized subcutaneously with antigens in Complete Freund's adjuvant, followed by screening sera via flow cytometry on MHCII-expressing cells pulsed with FR peptides. Competitive assays with TCR-Fc fusion proteins confirmed blocking. Hybridomas yielded monoclonal iTabs like 11-72, validated in reporter T cell lines measuring NFAT activation and IL-2 production.
- Immunization with HEL48-70 (FR+) induced iTabs; HEL48-61 (no FR) did not.
- Cryo-electron microscopy (3.09 Å resolution) revealed iTab Fab contacting peptide groove, C-terminal tryptophans (W62, W63), and MHCII residues (e.g., Y60β).
- Mutations in FR or MHCII abolished binding, confirming composite epitope.
Mass spectrometry verified natural FR peptides on MHCII, dependent on invariant chain and H2-M.
Validating Suppression: In Vitro and In Vivo Evidence
iTabs dose-dependently inhibited TCR binding, T cell proliferation (³H-thymidine), and cytokine secretion (IL-2 ELISA). In delayed-type hypersensitivity (DTH) models, monoclonal iTabs reduced footpad swelling. Antibody-dependent cellular cytotoxicity (ADCC) depleted antigen-presenting cells (APCs), further curbing responses.
Pre-immunization with mutated FR peptides (non-TCR stimulatory) induced iTabs that cross-suppressed wild-type responses, highlighting vaccine-like potential.
Triumph in EAE Model: A Step Toward Autoimmunity Treatment
In experimental autoimmune encephalomyelitis (EAE), a multiple sclerosis model, PLP139-151 immunization induced iTabs. Treatment with anti-PLP monoclonal iTab (2036) delayed onset, reduced severity (p<0.0001), and lowered IFN-γ/IL-17. Pre-immunization with FR-mutated PLP(H147K) prevented disease via iTab induction.
This antigen-specific approach spares beneficial immunity, contrasting broad immunosuppressants. With MS incidence rising in Japan, this holds promise.
Broader Horizons: Cancer Immunotherapy and Allergies
Beyond autoimmunity, iTabs could fine-tune T cell responses in allergies (e.g., suppressing allergen-specific helpers) or enhance cancer immunotherapy by preventing Treg-mediated exhaustion of anti-tumor T cells. While CAR-T therapies for autoimmunity emerge globally, iTabs offer passive, precise modulation.
In Japan, where CAR-T research advances for rheumatic diseases, iTabs complement by targeting helper T cells directly.
Read the full Nature Communications paper for detailed methodologies and data.The Critical Role of Flanking Residues
Naturally processed peptides often bear FR due to open MHCII groove. The study showed FR dictate iTab specificity and efficacy, explaining why minimal peptides fail. Chimeric peptides swapped FR, transferring iTab induction, underscoring evolutionary adaptation for precise regulation.
- C-terminal FR (e.g., WWA in HEL) for HEL epitope.
- N-terminal FR (e.g., PKS in Sm-P40).
- Design principle: Incorporate FR in peptide vaccines for iTab harnessing.
Osaka University's Legacy in Immunology
Osaka University's IFReC, a World Premier International Center, fosters interdisciplinary immunology, collaborating with Chugai and Otsuka for translational research. BIKEN complements with microbial pathogenesis expertise. Together, they propel Japan’s immunology dominance, with Osaka U often #1 globally in citations.
This discovery exemplifies how Japanese higher education drives biotech innovation amid national priorities like aging population and chronic diseases.
Japan's Autoimmune Landscape and Research Momentum
Japan faces high RA burden (1%), SLE (~74k cases), prompting investments in T cell modulation. Emerging CAR-T trials signal shift to cell therapies, where iTabs could synergize by regulating helpers.
Universities like Osaka lead, supported by MEXT funding and industry ties.
Photo by Hiroyuki Sen on Unsplash
Future Directions and Clinical Translation
Challenges: Sustaining iTab levels chronically, human translation (mouse model limitations). Opportunities: Humanized models, peptide vaccines for RA/MS trials, combo with checkpoint inhibitors.
Arase Lab's focus on MHCII neo-antigens positions them for neo-self therapies. Global impact: Licensed iTabs for precision immunology.
BIKEN achievement page details further.- Short-term: Validate in non-human primates.
- Medium-term: Phase I peptide vaccines.
- Long-term: iTab biologics for refractory autoimmunity.
This Osaka breakthrough heralds targeted immune control, advancing Japanese research globally.